1 9 6 1 [ 講堂 ]2F 8 : 45-8 : 55 8 : 55-11 : 00 1 S1-1 1,2 1 2 S1-2 1 1 2 3 1 2 3 S1-3 1,2 1,2 1 2 S1-4 MALDI 1 2 1 2 S1-5 12 : 00-13 : 00 1 LS1 12
14 : 00-14 : 40 14 : 40-15 : 10 15 : 10-16 : 00 LC/MS/MS 1,2 1 2 16 : 05-17 : 00 Novel strategies and applications of enhanced shotgun lipidomics for metabolism and translational research: Lipidomics sheds light on diabetic neuropathy Xianlin Han 1,2 1 Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, TX, USA, 2 Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, TX, USA 13
17 : 05-18 : 20 2 S2-1 1,2,3,4 1 2 3 4 S2-2 1,2,3,4 1 2 3 4 S2-3 Garuda Platform 1 1 1,2 1,2 2 3 3 3 3 1 3 2 1,2 1 2 3 S2-4 1 1 1 1 1 1 2 3 4 4 4 1 2 3 4 2 [ 小講堂 ]1F 9 : 00-11 : 00-1 (P-7) -2 (P-13) -3 (P-23) Girard P LC/ESI-MS/MS 1 1 1 2 3 4 1 1 2 3 4 LC-MS/MS 1 1,2 3,4 1 1 2 3 4 MALDI-TOF MS 14
-4 (P-37) -5 (P-49) -6 (P-69) -7 (P-77) -8 (P-78) HepG2 nanoesi-ms 1 玥 1 1 1 荣 2 1,3 1 1 2 3 LC/MS/MS 1,2,3 1 4 2 3 1 1 2 3 4 MALDIIn Situ 1 2 3 4 2 1,2 1 2 3 4 LC-MS/MS IDUA, IDS, NAGLU, GALNS, ARSB 1,2 2 2 3 3 4 4 1,6 6 1 1 2 1 2 3 4 5 6 PESI/MS/MS Scheduled SRM 1 2,3 4 1 1 2 4 1 1 1,3 1 2 3 4 12 : 00-13 : 00 2 LS2 LC/ESI-MS/MS D 15
3 [ 第 3 会議室 ]1F 10 : 00-10 : 55 TF-1 TF-2 2018 TF-3 LC/MS/MS TF-4 [ ホール ]1F 11 : 00-12 : 00 P-1 1 2 1 1 2 1 1 2 P-3 -N- Shimane CoHRE Study 1 2 3 3 4 2 1 2 3 4 P-5 LC-MS/MS 1 2 1 1 3 2 4 4 2 1 2 3 4 16
P-7 Girard P LC/ESI-MS/MS 1 1 1 2 3 4 1 1 2 3 4 P-9 4 Girard LC/ESI-MS/MS P-11 SPEUPLC-Q-Tof-MS 1 1 1 1,2 1,3 4 1 5 1 1 1 2 3 4 5 P-13 LC-MS/MS 1 1,2 3,4 1 1 2 3 4 P-15 GCMS 2,3-dihydroxyl-2-methybutyrate P-17 LC/MS 1 1 1 1 玥 1 1 1 2 2,3 4 2 1,5 1 1 2 3 4 5 P-19 1 2 玥 2 2 2 2,3 4 5,6 6 6 1 2 3 4 5 6 P-21 LC-MS/MS 1 2 1 3 2,4 2 1 2 3 4 P-23 MALDI-TOF MS P-25 MBT Compass Bacteroides fragilis cfia 17
P-27 TMS GC/MS TMS 1 1 1 1 1 2 1 1 2 P-29 2 1 2 3 3 1 2 3 P-31 2-AG P-33 AST-120 1 2 3 1 2 4 1 1 1 2 3 4 P-35 1,2,3 1,2 1,2,4 1 2 3 4 P-37 HepG2 nanoesi-ms 1 玥 1 1 1 荣 2 1,3 1 1 2 3 P-39 1,2 2 3 1 2 1 1 2 3 P-41 LC/HR-MS/MS 1 2 2 2 玥 1 2 1,3 1 1 2 3 P-43 SAMP10 ICP-MS/MS 1,2 1 1 1 1 2 3 1 2 3 P-45 1,1'-sulfonylbis 2- methylsulfinyl ethane SBMSE LC-MS/MS 18
P-47 GC-MS P-49 LC/MS/MS 1,2,3 1 4 2 3 1 1 2 3 4 P-51 ICP-MS 1 1 1 2 2 1 1 1 2 P-53 RNA 1 1 1 1 2 1 1 3,4 1,4 1 2 3 4 P-55 LC-QTRAP-MS/MS LC-Orbitrap-MS/MS 3 5F-NNEI 1 2 2 1 1 1 3 3 1 1 1 2 3 P-57 DSMS P-59 DSMS P-61 1 1 1,2 1,2 1 2 P-63 1 2 2 3 3 2 1,4 1 2 3 4 P-65 1 2 1 2 19
P-67 DIUTHAME 1 2 2 2 1 2 P-69 MALDIIn Situ 1 2 3 4 2 1,2 1 2 3 4 P-71 LC-MS/MS 1 1 玥 1 1 1,2 1 1 2 P-73 Validation of a multi-analyte flow-injection high resolution / accurate mass method for the quantification of acidic lipid species in human serum Dayan Goodenowe 1, Yanqiu Jiang 1, Vijitha Senananake 1, Yasuyo Yamazaki 1, Mamoru Satoh 2, Fumio Nomura 2 1 Prodrome Sciences Inc. Saskatoon, Canada, 2 Division of Clinical Mass Spectrometry, Chiba University Hospital P-75 5-FU dihydropyrimidine dehydrogenase 1 1 2 2 1 3 1,3 1 2 3 P-77 LC-MS/MS IDUA, IDS, NAGLU, GALNS, ARSB 1,2 2 2 3 3 4 4 1,6 6 1 1 2 1 2 3 4 5 6 P-79 PESI/MS/MSin vivo 1,2 1,3 4 3 3 4 2 1 2 3 4 P-81 FBRA LC-MS 1 2 3 3,4 3,4 4 5 5 1 2 3 4 5 P-83 ursolic acid 1 2 1 1 2 20
P-85 Lead-induced alterations in lipid hemostasis in human liver (HepG2) cells and protection with rosmarinic and ascorbic acids Yonghan LI 1, Wageh Sobhy DARWISH 1,2, Zhen CHEN 1, Yue WU 1, Hitoshi CHIBA 3, Shu-Ping HUI 1 1 Laboratory of lipid analysis, Faculty of Health Sciences, Hokkaido University, Kita 12, Nishi 5, Sapporo, Japan, 2 Food Control Department, Faculty of Veterinary Medicine, Zagazig University, 44519, Zagazig, Egypt, 3 Department of Nutrition, Sapporo University of Health Sciences, Nakanuma Nishi 4-2-1-15, Higashi Ku, Sapporo 007-0894, Japan P-87 HepG2 1 1 1 玥 1 1,2 1 1 2 P-89 ICP-MS/MS 1 1 2 3 4 4 1 2 3 4 13 : 00-14 : 00 P-2 HIBCH1 1 1 2 2 2 婷婷 2 1 2 P-4 GC/MS TCA 1 2 2 1 1 婷婷 1 1 1 2 P-6 1 1 1 2,3 1,3 1 2 3 P-8 MALDI-TOF MS VITEK MS Staphylococcus pettenkoferi 1 1 1 1 1 1 1 1 1 1 1 2 1 1 2 P-10 1 婷婷 P-12 21
P-14 1 1 2 1 1 3 2 2 1,3 1 2 3 P-16 LC/MS/MS/ 1α,25-D 1 2 3 1 1 3 2 1 2 3 P-18 N 1 2 1 1 1,2 2 3 3,4 1 2 3 4 P-20 1 1 2 2 1 3 1 1 2 3 P-22 Salmonella 1 P-24 MALDI Klebsiella oxytoca 1 2 1 1 1 1 1 1 3 1 4 1 2 3 4 P-26 I 1 婷婷 1 2 3 1 1 2 1 2 P-28 P-30 HILIC-MS/MS 1 1 1 2 2,3 2 1 2 3 P-32 LC-QTOF/MS 1 1 1,2 1,3 1 1 1,3 1 2 3 22
P-34 LC-MS/MSDNA 1 2 3 4 2 1 2 3 4 P-36 LC-MS/MS B-9 1 2 2 2 3 1,2 1 2 3 P-38 1 1 玥 1 1 荣 2 1,3 1 1 2 3 P-40 LC/Orbitrap-MS 玥 1 2 1 3 3 3 3 1,4 1 1 2 3 4 P-42 1,2 2 2 2 1,2 1 2 P-44 LC-MS/MS in vivo triazolam 1 2,3 2 1 1 1 2 3 P-46 GC-MS P-48 LC-MS/MS / P-50 LC-MS/MS TSPO 1,2 1 1 2 2 1 2 1,3 1 2 3 P-52 LC/DMSO-assisted ESI-QTOF-MS P-54 NMDA CB 1 1 2 3,4 5 1 5 1 1 5 1,4 1 2 3 4 5 23
P-56 DSMS 1 1 1 1 1,2 1,3 1 2 3 P-58 DSMS P-60 DSMS 5 P-62 1 2 1 1 4 1,3 1,4 1 2 3 4 P-64 1 2 1 3 4 2 2 1 1 2 3 4 P-66 1 1 1 2 3 3 4 5 1 1 1 2 3 4 5 P-68 1 1 2 3 3 4 1 1 1 1 2 3 4 P-70 GC-MS/MS 1 2,3 4 1 1 1 1,3 1 2 3 4 P-72 GC-MSprototype, 1 1 1 1 1 2 3 3 1 2 3 24
P-74 LC-MS/MS TCA 1 2 2 2 2 1 2 P-76 LC-MS P-78 PESI/MS/MS Scheduled SRM 1 2,3 4 1 1 2 4 1 1 1,3 1 2 3 4 P-80 ATLAS LC/Q-TOFMS 1 1 1 1 2 2 3 3 4 4 1 1 1 2 3 4 P-82 1,2 1,2 2,3 2,4 1,2 1,2,5 1,2 1 2 3 4 5 P-84 Estimation of cadmium residues in animal byproducts using ICP/MS: Health risk assessment, in-vitro cadmium induced adverse effects and protection with ascorbic and rosmarinic acids Wageh Sobhy Darwish 1,2, Hitoshi CHIBA 3, Shu-Ping HUI 1 1 Laboratory of lipid analysis, Faculty of Health Sciences, Hokkaido University, Kita 12, Nishi 5, Sapporo, Japan, 2 Food Control Department, Faculty of Veterinary Medicine, Zagazig University, 44519, Zagazig, Egypt, 3 Department of Nutrition, Sapporo University of Health Sciences, Nakanuma Nishi 4-2-1-15, Higashi Ku, Sapporo 007-0894, Japan P-86 1 1 2 玥 1 1,3 2 1 1 2 3 P-88 1 2 2 3 玥 2 3 1,2,4 1,2 1 2 3 4 25